Patents by Inventor Charles Zacharchuk

Charles Zacharchuk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antineoplastic combinations with mTOR inhibitor, trastuzumab and/or HKI-272
    Patent number: 10729672
    Abstract: A combination of temsirolimus and trastuzumab in the treatment of cancer is provided. A combination of temsirolimus and HKI-272 is provided. A combination of a trastuzumab and a HKI-272 is also provided. Regimens and kits for treatment of metastatic breast cancer, containing trastuzumab, temsirolimus and/or HKI-272, optionally in combination with other anti-neoplastic agents, or immune modulators are described.
    Type: Grant
    Filed: April 30, 2013
    Date of Patent: August 4, 2020
    Assignee: Wyeth LLC
    Inventors: Laurence Moore, Charles Zacharchuk, Sridhar K. Rabindran
  • Antineoplastic Combinations with mTOR Inhibitor, Trastuzumab and/or HKI-272
    Publication number: 20120308560
    Abstract: A combination of temsirolimus and trastuzumab in the treatment of cancer is provided. A combination of temsirolimus and HKI-272 is provided. A combination of a trastuzumab and a HKI-272 is also provided. Regimens and kits for treatment of metastatic breast cancer, containing trastuzumab, temsirolimus and/or HKI-272, optionally in combination with other anti-neoplastic agents, or immune modulators are described.
    Type: Application
    Filed: April 24, 2012
    Publication date: December 6, 2012
    Applicant: Wyeth LLC
    Inventors: Laurence Moore, Charles Zacharchuk, Sridhar K. Rabindran
  • SRC ACTIVATION FOR DETERMINING CANCER PROGNOSIS AND AS A TARGET FOR CANCER THERAPY
    Publication number: 20100081666
    Abstract: Methods of cancer diagnosis and prognosis using biomarkers.
    Type: Application
    Filed: July 14, 2009
    Publication date: April 1, 2010
    Applicant: Wyeth
    Inventors: Christina M. COUGHLIN, Michael E. BURCZYNSKI, Marisa P. DOLLED-FILHART, Robert PINARD, Donald WALDROM, Charles ZACHARCHUK, Frederick IMMERMANN, Maha KARNOUB, Jason CHRISTIANSEN, Mark GUSTAVSON, Annette MOLINARO, Alpana Waldron
  • ANTINEOPLASTIC COMBINATIONS WITH mTOR INHIBITOR, TRASTUZUMAB, AND/OR HKI-272
    Publication number: 20090297519
    Abstract: A combination of temsirolimus and trastuzumab in the treatment of cancer is provided. A combination of temsirolimus and HKI-272 is provided. A combination of a trastuzumab and a HKI-272 is also provided. Regimens and kits for treatment of metastatic breast cancer, containing trastuzumab, temsirolimus and/or HKI-272, optionally in combination with other anti-neoplastic agents, or immune modulators are described.
    Type: Application
    Filed: August 12, 2009
    Publication date: December 3, 2009
    Applicant: Wyeth
    Inventors: Laurence Moore, Charles Zacharchuk, Sridhar K. Rabindran
  • Antineoplastic combinations with mTOR inhibitor,herceptin, and/or hki-272
    Publication number: 20070104721
    Abstract: A combination of temsirolimus and herceptin in the treatment of cancer is provided. A combination of temsirolimus and HKI-272 is provided. A combination of herceptin and HKI-272 is also provided. Regimens and kits for treatment of metastatic breast cancer, containing herceptin, temsirolimus and/or HKI-272, optionally in combination with other anti-neoplastic agents, or immune modulators are described.
    Type: Application
    Filed: November 2, 2006
    Publication date: May 10, 2007
    Applicant: Wyeth
    Inventors: Laurence Moore, Charles Zacharchuk, Sridhar Rabindran
  • Use of an epidermal growth factor receptor kinase inhibitor (EGFR) in gefitinib resistant patients
    Publication number: 20060235046
    Abstract: This invention discloses method of treating or inhibiting cancer in a human having at least one of an Exon 19 del E746-A750 and/or an Exon 21 point mutation comprising administering to said human gefitinib and/or iressa alone or in combination with other cytotoxic agents or chemotherapeutic agents and an effective amount of EGFR kinase inhibitor.
    Type: Application
    Filed: April 12, 2006
    Publication date: October 19, 2006
    Applicant: Wyeth
    Inventors: Charles Zacharchuk, Susan Quinn, Patricia Martins, Lee Greenberger, Ante Lundberg